Skip to main content
OpenTrials
Completed

NCT Number: NCT06743334

Secondary Databased Post-marketing Surveillance Study of BNT162b2

This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study is a retrospective, non-interventional, observational study using Korean Disease Control and Prevention Agency-COVID-19-National Health Insurance Service (K-COV-N) database that includes COVID-19 vaccination/infection and claims data in Korean population. For the primary objective, cohort and self-controlled design will be used for measure of occurrence and measure of association, respectively. For the secondary objective, cohort design will be used for measure of occurrence.

Primary objective:

  • To describe the frequency and estimate the incidence ratio of adverse events of special interest (AESIs) following exposure to Comirnaty Injection among individuals aged 6 months or older in the Republic of Korea
  • To evaluate the relative risk of AESIs following exposure to Comirnaty Injection among individuals aged 6 months or older in the Republic of Korea, using a self-controlled case series (SCCS) design

Secondary objective:

  • To describe the frequency and estimate the incidence ratio of severe COVID-19 outcomes (COVID-19 hospital admission, COVID-19 intensive care unit [ICU] admission, and COVID-19 death).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Primary Objectives 1-1. Measure of Occurrence Inclusion Criteria For the measure of occurrence, analytical populations will include following individuals,
  • Who meet the predefined criteria for each study population.
  • With enrollment in the national insurance during the observation period, as well as during the clean window prior to the start of the observation period.

Exclusion criteria

For the measure of occurrence, analytical populations will exclude following individuals,

  • With diagnosis of AESI during the AESI-specific clean window; or
  • With diagnosis of AESI between first dose and second/third dose of primary series when analyzing for the second/third dose.

1-2. Measure of Association Inclusion Criteria For the measure of association, analytical populations will include following individuals,

  • Who meet the predefined criteria for each study population.
  • With enrollment in the national insurance during the observation period, as well as during the clean window prior to the start of the observation period; and
  • Who had incident AESI during the observation period. Exclusion Criteria For the measure of association, analytical populations will exclude following individuals,
  • Who do not have both risk and control window time. If an individual disenrolls, dies, or reaches the end of the study period during the risk window prior to accumulating any control window time, he/she will be excluded; or
  • With a diagnosis of AESI during the AESI-specific clean window.
  • Secondary Objective Inclusion Criteria For the secondary objective, the study populations will include following individuals,
  • Who meet the predefined criteria for each study population. Exclusion Criteria
  • None

Treatment and study plan

Tozinameran (BNT162b2)

Biological
  • 12 years or older
  • Primary series: 2 doses, 30 μg each, administered 21 days apart
  • Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot
  • 5 to 11 years of age
  • Primary series: 2 doses, 10 μg each, administered 21 days apart
  • Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot
  • 6 months to 4 years of age
  • Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)

Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)

Biological
  • 12 years or older
  • Single booster dose, 15/15 μg, administered after ≥3 months after primary series

Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

Biological
  • 12 years or older
  • Single booster dose, 15/15 μg administered after ≥3 months after primary series

Primary outcomes

  1. Frequency of Adverse Events of Special Interest (AESI) - Measure of Occurrence

    Time frame: Up to 270 days after vaccination

    Measure of Occurrence (Cohort design) The frequency of AESIs will be analyzed.

  2. Incidence of Adverse Events of Special Interest (AESI) - Measure of Occurrence

    Time frame: Up to 270 days after vaccination

    Measure of Occurrence (Cohort design) The incidence of AESIs will be analyzed.

  3. Incidence of Adverse Events of Special Interest (AESI) - Measure of Association

    Time frame: Up to 270 days after vaccination

    Measure of Association (Self-Controlled Design) The incidence of AESIs will be analyzed.

Secondary outcomes

  1. Frequency of Severe COVID-19 Outcomes

    Time frame: Up to 150 days after vaccination

    The frequency of severe COVID-19 outcomes including COVID-19 hospital admission, COVID-19 Intensive care unit (ICU) admission, and COVID-19 death will be estimated.

  2. Incidence of Severe COVID-19 Outcomes

    Time frame: Up to 150 days after vaccination

    The incidence of severe COVID-19 outcomes including COVID-19 hospital admission, COVID-19 Intensive care unit (ICU) admission, and COVID-19 death will be estimated.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 19, 2024
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.